|
1
|
Liao Y, Guo Y, Li S, Wang L, Tang Y, Li T, Chen W, Zhong G, Song G. Structure-based design and structure-activity relationships of 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors. Bioorg Med Chem Lett 2018; 28:1188-1193. [DOI: 10.1016/j.bmcl.2018.02.056] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2018] [Revised: 02/26/2018] [Accepted: 02/27/2018] [Indexed: 11/26/2022]
|
|
2
|
Press NJ, Taylor RJ, Fullerton JD, Tranter P, McCarthy C, Keller TH, Arnold N, Beer D, Brown L, Cheung R, Christie J, Denholm A, Haberthuer S, Hatto JDI, Keenan M, Mercer MK, Oakman H, Sahri H, Tuffnell AR, Tweed M, Tyler JW, Wagner T, Fozard JR, Trifilieff A. Solubility-Driven Optimization of Phosphodiesterase-4 Inhibitors Leading to a Clinical Candidate. J Med Chem 2012; 55:7472-9. [PMID: 22889281 DOI: 10.1021/jm300459a] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Affiliation(s)
- Neil J. Press
- Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham,
West Sussex RH12 5AB, U.K
| | - Roger J. Taylor
- Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham,
West Sussex RH12 5AB, U.K
| | | | - Pamela Tranter
- Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham,
West Sussex RH12 5AB, U.K
| | | | | | | | - David Beer
- Novartis Institute for Tropical Diseases, 10 Biopolis
Road, 05-01 Chromos, 138670 Singapore
| | | | | | | | | | | | - Julia D. I. Hatto
- Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham,
West Sussex RH12 5AB, U.K
| | | | | | - Helen Oakman
- Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham,
West Sussex RH12 5AB, U.K
| | | | | | | | - John W. Tyler
- Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham,
West Sussex RH12 5AB, U.K
| | - Trixie Wagner
- Novartis Institutes for Biomedical Research, Lichtstrasse 35, CH-4056
Basel, Switzerland
| | - John R. Fozard
- Novartis
Distinguished Scientist, Novartis Institutes for Biomedical Research,
Lichtstrasse 35, CH-4056 Basel, Switzerland
| | - Alexandre Trifilieff
- Novartis Institutes for Biomedical Research, Lichtstrasse 35, CH-4056
Basel, Switzerland
| |
Collapse
|
|
3
|
The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia. Bioorg Med Chem Lett 2012; 22:1019-22. [DOI: 10.1016/j.bmcl.2011.11.127] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2011] [Revised: 11/29/2011] [Accepted: 11/30/2011] [Indexed: 01/06/2023]
|
|
4
|
Deninno MP, Andrews M, Bell AS, Chen Y, Eller-Zarbo C, Eshelby N, Etienne JB, Moore DE, Palmer MJ, Visser MS, Yu LJ, Zavadoski WJ, Michael Gibbs E. The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. Bioorg Med Chem Lett 2009; 19:2537-41. [PMID: 19339180 DOI: 10.1016/j.bmcl.2009.03.024] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2009] [Revised: 03/05/2009] [Accepted: 03/09/2009] [Indexed: 11/24/2022]
Abstract
Starting from a non-selective pyrazolo-pyrimidone lead, the sequential use of parallel medicinal chemistry and directed synthesis led to the discovery of potent, highly selective, and orally bioavailable PDE9 inhibitors. The availability of these tools allowed for a thorough evaluation of the therapeutic potential of PDE9 inhibition.
Collapse
Affiliation(s)
- Michael P Deninno
- Pfizer Global Research and Development, Groton Laboratories, Groton, CT 06340, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|